Company Description
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.
The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer.
It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jeffrey Lamothe |
Contact Details
Address: 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 United States | |
| Phone | 206 838 0500 |
| Website | aptevotherapeutics.com |
Stock Details
| Ticker Symbol | APVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671584 |
| CUSIP Number | 03835L702 |
| ISIN Number | US03835L7029 |
| Employer ID | 81-1567056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey G. Lamothe CA | Chief Executive Officer, President and Director |
| Marvin L. White | Executive Chair |
| SoYoung Kwon J.D., LL.M. | Corporate Secretary, Senior Vice President, General Counsel, Business Development and Corporate Affairs |
| Mary J. Janatpour Ph.D. | Senior Vice President and Chief Scientific Officer |
| Miriam Weber Miller | Vice President of Investor Relations and Corporate Communications |
| Dr. Dirk Huebner M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 3, 2026 | 424B4 | Prospectus |
| Sep 3, 2026 | 8-K | Current Report |
| Sep 2, 2026 | EFFECT | Notice of Effectiveness |
| Aug 31, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 26, 2026 | D | Notice of Exempt Offering of Securities |
| Aug 21, 2026 | PRE 14A | Other preliminary proxy statements |
| Aug 21, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |